Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP625220.RAqTOsXaWgSuF-ICcfq053POhS0xf3kiYLoxkn_NV00rY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP625220.RAqTOsXaWgSuF-ICcfq053POhS0xf3kiYLoxkn_NV00rY130_assertion type Assertion NP625220.RAqTOsXaWgSuF-ICcfq053POhS0xf3kiYLoxkn_NV00rY130_head.
- NP625220.RAqTOsXaWgSuF-ICcfq053POhS0xf3kiYLoxkn_NV00rY130_assertion description "[Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625220.RAqTOsXaWgSuF-ICcfq053POhS0xf3kiYLoxkn_NV00rY130_provenance.
- NP625220.RAqTOsXaWgSuF-ICcfq053POhS0xf3kiYLoxkn_NV00rY130_assertion evidence source_evidence_literature NP625220.RAqTOsXaWgSuF-ICcfq053POhS0xf3kiYLoxkn_NV00rY130_provenance.
- NP625220.RAqTOsXaWgSuF-ICcfq053POhS0xf3kiYLoxkn_NV00rY130_assertion SIO_000772 19917848 NP625220.RAqTOsXaWgSuF-ICcfq053POhS0xf3kiYLoxkn_NV00rY130_provenance.
- NP625220.RAqTOsXaWgSuF-ICcfq053POhS0xf3kiYLoxkn_NV00rY130_assertion wasDerivedFrom befree-20150227 NP625220.RAqTOsXaWgSuF-ICcfq053POhS0xf3kiYLoxkn_NV00rY130_provenance.
- NP625220.RAqTOsXaWgSuF-ICcfq053POhS0xf3kiYLoxkn_NV00rY130_assertion wasGeneratedBy ECO_0000203 NP625220.RAqTOsXaWgSuF-ICcfq053POhS0xf3kiYLoxkn_NV00rY130_provenance.